Glucagon receptor agonism: contributes to higher energy expenditure (shown strongly in preclinical work) and may add hepatic metabolic effectshelping explain broader metabolic outcomes beyond appetite alone
In addition to this, semaglutide GLP-1 also slows down the rate at which glucose is absorbed by the body, which can further help to reduce blood sugar levels
This material is not a drug, food, cosmetic, dietary supplement, or medical device and has not been evaluated by the FDA
These types of therapies therefore generally require high doses and long treatment durations, which increase the risk of undesirable side effects
To view a copy of this licence, visit About this article Cite this article DAmbrosio, M., White, M.E.H., Gavriil, E.S